Epidemiology of Norovirus Infection Among Immunocompromised Patients at a Tertiary Care Research Hospital, 2010–2013

Karin Bok,1,a,b D. Rebecca Prevots,2,a Alison M. Binder,2 Gabriel I. Parra,1 Sara Strollo,2 Gary A. Fahle,4 Allison Bohrle-Yardley,1 Jordan A. Johnson,1 Eric A. Levenson,1 Stanislav V. Sosnovtsev,1 Steven M. Holland,2 Tara N. Palmore,2,a and Kim Y. Green1

1Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), 2Laboratory of Clinical Infectious Disease, NIAID, 3Hospital Epidemiology Service, National Institutes of Health Clinical Center, and 4Microbiology Service, Clinical Center, National Institutes of Health, Bethesda, Maryland

Background. Noroviruses are a major cause of infectious gastroenteritis worldwide, and viruses can establish persistent infection in immunocompromised individuals. Risk factors and transmission in this population are not fully understood.

Methods. From 2010 through 2013, we conducted a retrospective review among immunocompromised patients (n = 268) enrolled in research studies at the National Institutes of Health Clinical Center and identified a subset of norovirus-positive patients (n = 18) who provided stool specimens for norovirus genotyping analysis.

Results. Norovirus genome was identified by reverse-transcription quantitative polymerase chain reaction in stools of 35 (13%) of the 268 immunocompromised patients tested, and infection prevalence was 21% (11 of 53) in persons with primary immune deficiencies and 12% (20 of 166) among persons with solid tumors or hematologic malignancies. Among 18 patients with norovirus genotyping information, norovirus GII.4 was the most prevalent genotype (14 of 18, 78%). Persistent norovirus infection (≥6 months) was documented in 8 of 18 (44%) individuals. Phylogenetic analysis of the GII.4 capsid protein sequences identified at least 5 now-displaced GII.4 variant lineages, with no evidence of their nosocomial transmission in the Clinical Center.

Conclusions. Norovirus was a leading enteric pathogen identified in this immunocompromised population. Both acute and chronic norovirus infections were observed, and these were likely community-acquired. Continued investigation will further define the role of noroviruses in these patients and inform efforts toward prevention and treatment.

Keywords. epidemiology; immunocompromised; norovirus.

Norovirus is an important cause of gastroenteritis among both adults and children in the United States, and its relative role as a serious diarrheal pathogen in children is increasing in countries where the rotavirus vaccine is routinely administered [1–3]. Noroviruses cause an estimated 800 deaths per year in the United States, there emerging as the second most important cause of mortality due to gastroenteritis after Clostridium difficile [4]. Norovirus vaccines are in development, and vaccines based on virus-like particles have shown promise in early clinical trials [5–8]. In addition, a virus-specific monoclonal antibody was able to prevent a homologous norovirus infection in chimpanzees [9, 10].

Noroviruses are nonenveloped icosahedral viruses of 28–30 nm in diameter, and they contain a single-stranded, positive sense ribonucleic acid (RNA) genome [11]. The genome is organized into 3 open reading frames (designated ORF1, ORF2, and ORF3), which encode a nonstructural polyprotein (NS1-7), the major capsid protein (VP1), and a second structural protein (VP2), respectively. Noroviruses are characterized by a high degree of genomic and antigenic diversity and are currently classified into 7 genogroups, GI–GIVI, but only genogroups GI, GII, and GIV infect humans. Of these, GI is subdivided into 9 genotypes, whereas GII consists of 22 genotypes [12, 13]. Although most of the genotypes have been described as circulating worldwide with variable incidences, a single genotype, GII.4, is the most prevalent [14, 15]. The reasons for the dominance of this particular genotype are not clear, but it is speculated that a new variant of GII.4 norovirus evolves to escape herd immunity every 3 to 4 years [15–17]. Noroviruses are increasingly recognized as an important cause of gastroenteritis in immunocompromised patients [18–23]. Patients with deficient immune responses resulting from a congenital disorder, immunosuppressive therapy, cancer treatment, or human immunodeficiency virus (HIV) infection may become chronically infected, with prolonged virus shedding and illness. To better understand the epidemiology

Received 16 May 2016; accepted 5 August 2016.

1This manuscript is dedicated to the memory of Dr. Albert Z. Kapikian (1930–2014), who discovered noroviruses in 1972 and dedicated his life to improving the lives of children and adults affected by gastroenteritis. He was our most influential mentor and friend.

2K. B. and D. R. P. are co-first authors.

3Present Affiliation: National Vaccine Program Office, Office of the Assistant Secretary for Health, Department of Health and Human Services, Washington, District of Columbia.

Correspondence: K. Y. Green, Caliciviruses Section, Laboratory of Infectious Diseases, NIAID, NIH, 50 South Drive, Bldg. 50, Room 6618, Bethesda, MD 20892 (kgreen@niaid.nih.gov).

Open Forum Infectious Diseases®

Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US. DOI: 10.1093/ofid/ofw169

Norovirus in Immunocompromised Patients • OFID • 1
of noroviruses in immunocompromised populations, we studied a cohort of patients referred to the National Institutes of Health (NIH) Clinical Center for treatment. We present a retrospective epidemiologic analysis of this population tested for norovirus at the NIH and provide insight into the molecular epidemiology of the noroviruses in this setting.

MATERIALS AND METHODS

Study Population
Persons referred to the NIH Clinical Center, a 240-bed clinical research hospital, were enrolled in a variety of Institutional Review Board (IRB)-approved research protocols, including those related to immunocompromising conditions, such as immune suppression resulting from cancer therapy, stem cell transplantation (SCT), primary immunodeficiencies (PIDs), and acquired immune deficiencies. Solid organ transplants were not performed at the NIH Clinical Center. Patients presenting with acute gastroenteritis were placed in contact isolation according to hospital protocol, and stool samples were submitted to the NIH Clinical Center. Most patients who tested positive for enteric infectious pathogens remained in contact isolation until symptoms resolved; SCT recipients remained in isolation until follow-up test results were negative.

We defined 2 separate study populations for this investigation. Patients eligible for the retrospective cohort analysis were immunodeficient patients enrolled in any NIH protocol and for whom a norovirus test was ordered. The analysis spanned an 18-month period from September 22, 2011 through March 23, 2013, which corresponded to the establishment of an in-house reverse-transcription (RT) quantitative polymerase chain reaction (PCR) assay for diagnosis of norovirus infection. The retrospective analysis of this cohort was conducted as part of a quality improvement study for the hospital and determined to be exempt from IRB review by the NIH Office of Human Subjects Research Protections. The second study population was defined as norovirus PCR-positive patients from whom informed consent was obtained to perform genetic characterization of viruses in clinical specimens under an IRB-approved NIH protocol for viral pathogens. The genetic characterization study was initiated before the introduction of in-house norovirus testing, when stool samples were sent from the NIH Microbiology Service to a commercial diagnostic laboratory; this study included patients enrolled from April 2010 through November 2013.

Data Collection and Analysis
Demographic, clinical, and laboratory information was abstracted from medical records. The underlying diagnosis was determined based on detailed medical record review and consultation with attending physicians as needed. In addition, medical records were reviewed to identify results for other viral, bacterial, or parasitic pathogens that were identified within the 30 days before and after norovirus testing. To ensure a representative sample, we have included only tests for which at least half the study population was tested. All analyses were conducted with SAS version 9.2 (SAS Institute Inc., Cary, NC).

Norovirus Reverse Transcription-Quantitative Polymerase Chain Reaction Detection
Stool samples were collected in a sterile container and stored at 4°C before processing. Liquid or formed stool was diluted in S.T.A.R. stool transport and recovery buffer (Roche Diagnostics Corporation, Madison, WI) to create a 10% suspension and then clarified by low-speed centrifugation at 1000 × g for 1 minute. Viral RNA was isolated from 200 µL of the clarified stool supernatant using the NucliSENS easyMAG automated extractor system (BioMerieux, Durham, NC). Norovirus detection was performed using a quantitative real-time TaqMan RT-PCR as described previously [24] with minor modifications in instrumentation and reaction conditions noted below. Primers and probes were designed to detect a broad range of GI and GII noroviruses when combined for use in a multiplex assay. For detection of GI noroviruses, the forward (COG1F) and reverse (COG1R) primers consisted of 5′-CGTTYGATGCGNTTY CATGA-3′ and 5′-CTTAGACGCCATCATCATTTYAC-3′, respectively, and the probe (RING1a-TP and RING1b-TP) were 5′-FAM-AGATYGCATCCTCGATC-TAMRA-3′ and 5′-FAM-AGATCAGATGTCTCTGTCCATA-TAMRA-3′. For detection of GII noroviruses, the forward (COG2F) and reverse (COG2R) primer sequences were 5′-CARGARCNATGT TYAGRGTGATGAG-3′ and 5′-TCGAGGCATCTTCATT CACA-3′, respectively, and the probe (RING2-TP) was 5′-Cy5-TGGGAGGGCGATCGCAATCT-Iowa Black RQ-3′. Real-time PCR was performed on the ABI 7500 instrument (Life Technologies, Carlsbad, CA) in a 20 µL reaction consisting of 1× TaqMan Fast Virus 1-step master mix (Thermo Fisher Scientific, Waltham, MA), 0.9 µM each primer set (both GI and GII), 12.5 µM of each probe (both GI and GII), and 10 µL purified nucleic acid. The reaction mixture was then incubated at 50°C for 5 minutes, 95°C for 20 seconds, followed by 40 cycles at 95°C for 3 seconds and 60°C for 30 seconds. Before extraction, each clarified stool aliquot was spiked with an internal control (pBR322 plasmid DNA) to verify successful recovery of nucleic acid and removal of PCR inhibitors. The internal control in extracted samples was detected by amplification in a separate real-time PCR as described previously [25]. Known norovirus-positive and -negative stools were included in each run.

Norovirus Genotyping and Capsid Sequencing
A total of 28 norovirus-positive stool samples from 18 patients were collected for genotyping. A partial polymerase gene sequence was first obtained using a conventional RT-PCR diagnostic method described previously [26]. In brief, the polymerase gene was amplified using a cocktail of primers
(289hi and 290hijk), and a deoxyribonucleic acid (DNA) ampli-
con of approximately 300 base pairs (bp) was excised from the
gel and purified using a QIAGEN spin column (QIAGEN, Ger-
mantown, MD). The nucleotide sequence was determined di-
rectly from the amplicon using a Big Dye Terminator Cycle
Sequencing Ready Reaction Kit, version 3.0 (Applied Biosys-
tems, Carlsbad, CA), and an ABI PRISM 3730 automated
dNA sequencer (Applied Biosystems). An online norovirus
typing tool was used to provisionally assign the norovirus
strain group [27], followed by capsid gene amplification with
primer pairs GI1SKF (5′-CTGCCCGAATTTGTAAGTAATGA-3′)
and GI1SKR (5′-CCCAACCCARCCATTATRACA-3′) or G2SKF
(5′-CNTGGGAGGCGATCGCAA-3′) and G2SKR (5′-
CCRCNCATRHCRTTTRTACAT-3′) for GI and GII
noroviruses, respectively [28]. The capsid gene amplicons
(approximately 300–400 bp) were sequenced directly, and the
genoype assigned with the online typing tool noted above.

Noroviruses of the GII.4 genotype from 13 patients were se-
lected for further characterization. For some samples, cDNA
was generated from the purified viral RNA using the Super-
script III First-Strand Synthesis Super Mix (Invitrogen) with ei-
ther oligo dT or random hexamers (Invitrogen) as primers,
followed by PCR with the Elongase System (Invitrogen). In
other samples, a one-step RT-PCR was carried out with the Su-
perscript III One Step RT-PCR System (Invitrogen) following
the manufacturer’s recommendations. Characteristically, an
approximately 1600-bp PCR amplicon containing ORF2 sequence
was generated with forward primer GIIF5050 (5′-GGGGCG
CGATCGCAATC-3′) corresponding to nucleotides 5049–
5065 of GII.4 strain MD145-12 (GenBank accession number
AY032605) and reverse primer GIIF6800RDC32 (5′-STTCCA
GTTCGCCATGGG-GG-3′) complementary to nucleotides 6683-
6665 of MD145-12. The amplicon was separated in a 1.2% aga-
rose gel, excised, and purified as above. The nucleotide sequence
was determined directly from the purified DNA amplicon using the
Big Dye Terminator Cycle Sequencing Ready Reaction Kit,
version 3.0, and GII.4-specific primers as previously reported
[29,30], and the sequencing products were resolved as described above.

Phylogenetic and Structural Analyses
Phylogenetic analysis was performed on the ORF2 nucleotide
sequences (23 total) obtained from 13 NIH immunocompro-
mised patients with GII.4 norovirus and the reference strains
for each of the major GII.4 variant groups [12]. Sequence align-
ments were performed with Clustal W and manually edited.
The phylogenetic tree was inferred using the Neighbor-Joining
reconstruction method and Kimura 2-parameter as a model of
nucleotide substitution as implemented in MEGA, version 6
[31]. The statistical significance of the phylogenies constructed
was estimated by bootstrap analysis with 1000 pseudo-replicate
data sets. The molecular model of the P domain of the VP1 of
Patient A was rendered using the x-ray coordinates from the
GII.4 strain VA387 (Protein Data Bank accession number
2OBR) and Chimera 1.8 [32].

Detection of Bacterial and Other Viral Enteric Pathogens in Stool
Bacterial culture (sheep blood agar, MacConkey agar, xylose ly-
sine deoxycholate agar, and Campylobacter CVA agar) was used
for detection of Salmonella, Shigella, and Campylobacter species
following standard methods. The Cepheid Xpert C difficile assay
was used for detection of toxigenic C difficile, and the Premier
Adenocline-Type 40/41 and Premier Rotacine enzyme immu-
noassay test kits (Meridian Bioscience, Inc., Cincinnati, OH)
were used for the detection of adenovirus serotypes 40 and 41
and rotavirus, respectively. For detection of Giardia lamblia, the
ProSpecT Giardia Microtiter assay (Remel, Inc., Lenexa, KS)
was used.

RESULTS

Immunocompromised Study Population Tested for Norovirus as Part of
Clinical Care
From September 22, 2011 through March 23, 2013, we identi-
fied 281 patients at the NIH Clinical Center with at least 1 valid
(non-indeterminate) norovirus test result during the study pe-
riod. Of these, 13 were excluded from our analysis because their
underlying diagnoses were unrelated to primary or secondary
immunodeficiency; none of these patients were positive for nor-
ovirus. Among the 268 immunocompromised patients, the
mean age at the time of the first norovirus test was 42 years.
Overall, 168 (63%) were male; of those with race/ethnicity infor-
mation available, 73% were white and 18% were black/African
American. The most common underlying diagnoses of those
tested during the study period included those with hematologic
malignancies (n = 122; 46%), PIDs (n = 53, 20%), and solid tu-
mors (n = 44, 16%) (Table 1). In the group of 53 patients with
PID disorders, the most common diagnoses were chronic gran-
ulomatous disease (n = 13; 25%) and GATA2 deficiency [33]
(n = 10, 19%).

Norovirus was identified in 35 (13%) of the 268 immuno-
compromised patients (Table 1). Among these 35 patients who
tested positive, 20 (57%) reported an acute onset of disease,
with 17 (85%) of these illnesses occurring during the winter
months of November–March. Six of these patients reported
similar gastrointestinal illnesses among family members,
although family history information was not systematically
collected. The most common presenting symptoms were diar-
rhea (95%) and vomiting (55%). Among those without an
acute onset noted at the time of testing, 9 (27%) presented
with a history of chronic diarrhea, 8 of whom had a PID and
1 of whom had HIV/acquired immune deficiency syndrome
(AIDS). Patients who tested positive for norovirus had a
mean of 2.4 positive tests (range, 1–11). Among the 17 with
more than 1 positive test, the median interval between first
and last positive tests during the study period was 46 days

Norovirus in Immunocompromised Patients • OFID • 3
Among the 20 patients with acute onset, 10 were admitted to the clinical center and 6 were tested for norovirus within 3 days of admission (median, 1.5 days; range, 0–23 days). Of the remaining 15 without an acute onset, 7 were tested for norovirus following an admission to the Clinical Center, 2 within 3 days (median, 5 days; range, 1–284 days).

The prevalence of norovirus shedding varied by diagnosis. Among those with PID, norovirus was relatively common, with 11 (21%) of 53 testing positive. For the 166 patients with solid tumors or hematologic malignancies, 20 (12%) were positive, and among those with HIV/AIDS, 3 (23%) of 7 were positive (Table 1). Overall, 11 (31%) of the 35 with norovirus infection were SCT recipients.

The distribution of blood group in the norovirus-positive cohort was as follows: O, 38%; A, 28%; B, 22%; and AB, 12%. No apparent correlation was observed between blood group and infection with a particular norovirus genotype (Table 2). The secretor status, which determines the phenotypic expression of histo-blood group antigen carbohydrates on the intestinal epithelium [34], was not available.

At the time of initial norovirus testing, most patients were receiving treatment for an underlying condition, which included steroids (14; 40%), T-cell immunomodulators (10; 29%), and therapeutic monoclonal antibodies (3; 9%). Of the 9 norovirus-positive patients who had received intravenous immune globulin in the month before testing, all had a PID.

The most common copathogen identified at the time of initial norovirus testing was *Clostridium difficile*, which was identified in 39 (16%) of the 251 immunocompromised patients tested (Table 1). Of the 32 patients positive for norovirus who were also tested for *Clostridium difficile*, 3 (9.4%) had both pathogens. Among 29 patients positive for norovirus and also tested for *Campylobacter*, none were positive for both. Most patients tested for norovirus had no other enteric pathogen identified (Table 1).

### Norovirus Characterization

One goal of this study was to establish whether an endemic nosocomial norovirus strain was being transmitted in the Clinical Center that could place immunocompromised patients at risk for norovirus infection during inpatient and outpatient visits. Between April 2010 and February 2013, stool samples were collected from 18 norovirus-positive patients (designated here as A through R) with a number of underlying conditions (Table 2), 15 of whom were also included in the epidemiologic analysis. Norovirus RNA was extracted from stool, and virus-specific RT-PCR amplicons were sequenced. The capsid genotype was assigned using the norovirus online typing tool [27]. Norovirus GII.4 was the most common genotype detected (14 of 18), comprising 78% of the samples, followed by GII.3 (1 of 18, 5%), GII.2 (1 of 18.5%), GII.1 (1 of 18, 5%), and GII.3 (1 of 18, 5%) (Table 2). The duration of shedding, as determined by

---

**Table 1. Prevalence of Norovirus and Other Pathogens Identified at the Time of Norovirus Testing**

| Pathogen                  | Hematologic Malignancies (n = 122) | Autoimmune/Autoinflammatory (n = 7) | Other Hematologic (n = 20) | Total (n = 268) |
|---------------------------|------------------------------------|-------------------------------------|----------------------------|-----------------|
| Norovirus                 | 122 (100)                          | 7 (100)                             | 12 (60)                    | 241 (90)        |
| *Clostridium difficile*   | 119 (100)                          | 5 (100)                             | 12 (60)                    | 136 (50)        |
| *Campylobacter*           | 114 (100)                          | 7 (100)                             | 12 (60)                    | 133 (50)        |
| *Shigella*                | 89 (100)                           | 7 (100)                             | 12 (60)                    | 108 (40)        |
| *Adenovirus*              | 92 (100)                           | 7 (100)                             | 12 (60)                    | 111 (40)        |
| *Rotavirus*               | 101 (100)                          | 7 (100)                             | 12 (60)                    | 119 (40)        |

**Abbreviations:** AIDS, acquired immunodeficiency syndrome; HIV, human immunodeficiency virus; pos, positive.

* Concurrent pathogens defined as testing done within 30 days before or after norovirus test.
* In the first "n", refers to the number tested for each pathogen.
the consistent detection of norovirus genome in the available stool samples collected over the time period of this study, is noted in Table 2. Sequencing analysis confirmed the presence of a single genotype within each patient during periods of prolonged shedding.

**Norovirus Evolution in Immunocompromised Patients**

Twenty-three stool samples from 13 patients with GII.4 norovirus were selected for further sequencing of the major capsid gene (Figure 1). Norovirus GII.4 has been the predominant global genotype for several decades, and new GII.4 variants (named according to an early location where first detected) emerge periodically to displace the predominant GII.4 strain associated with disease [35]. Comparison of the NIH GII.4 viruses with GII.4 variant reference strains showed that most of the viruses, with the exception of the viruses from Patient M and Patient O (data not shown ) clustered with an established variant group, including Den Haag 2006b, Osaka 2007, and New Orleans 2009 (Figure 1A). The Sydney 2012 GII.4 variant (designated on the dendrogram as Hu/GII.4/NSW0514/AU/2012/JX459908), first identified in Australia in March 2012 [36] and responsible for nearly half the gastroenteritis outbreaks in the United States by October 2012 [37], was not detected.

Several noroviruses clustered within the same GII.4 variant group. The relatedness of the strains at the nucleotide and amino acid level and possible transmission patterns were examined (Figure 1B). Specifically, the noroviruses detected in patients D, E, F, H, I, J, and K all clustered within the New Orleans 2009 group. The highest identity in pairwise comparisons in the New Orleans cluster was observed among the sequential virus samples of Patient H. The second closest relationship in the New Orleans 2009 cluster was between the viruses from Patients F and I, with only 10 nucleotide differences in the ORF2 gene. No common link with regard to the timing of inpatient or outpatient visits or to room location was observed.

---

**Table 2. Immunodeficiency Diagnosis and Genotype Among Patients With Stool Samples Collected for Sequencing**

| Patient | Diagnosis | ABO Blood Group | Duration Norovirus Shedding (Days)* | Stool Collection Date | Stool Designation | Norovirus Genotype (GII.4 Variant) | GenBank Number |
|---------|-----------|----------------|-------------------------------------|-----------------------|------------------|-------------------------------------|---------------|
| A       | PID/Hyper IgM, stem cell transplant | A               | 939                                 | 4/1/2010              | A.1              | GII.4 (Apeldoorn 2007)             | KX608847      |
|         |           |                 |                                     | 6/15/2010             | A.2              | GII.4 (Apeldoorn 2007)             | KX608848      |
|         |           |                 |                                     | 12/20/2011            | A.5              | GII.4 (Apeldoorn 2007)             | KX608849      |
|         |           |                 |                                     | 10/20/2012            | A.13             | GII.4 (Apeldoorn 2007)             | KX608850      |
| B       | HIV/leukoencephalopathy/CD4 = 0 | AB              | 3                                   | 6/22/2010            | B.2              | GII.4 (Den Haag 2006b)             | KX608851      |
|         |           |                 |                                     | 6/23/2010             | B.3              | GII.4 (Den Haag 2006b)             | KX608852      |
|         |           |                 |                                     | 6/24/2010             | B.4              | GII.4 (Den Haag 2006b)             | KX608853      |
| C       | Leukemia/ALL | O               | 5                                   | 2/4/2011             | C.2              | GII.4 (Den Haag 2006b)             | KX608854      |
| D       | HIV/carcinoma CD4 = 8 | O               | 205                                 | 6/14/2011            | D.1              | GII.4 (New Orleans 2009)           | KX608855      |
| E       | PID/SCID   | A               | 554                                 | 11/22/2011           | E.1              | GII.4 (New Orleans 2009)           | KX608856      |
| F       | Hodgkin’s lymphoma | B               | 1                                   | 12/20/2011           | F.1              | GII.4 (New Orleans 2009)           | KX608857      |
| G       | PID/CVID   | O               | 1                                   | 12/15/2011           | G.1              | GII.4 (Osaka 2007)                 | KX608858      |
| H       | PID/CVID   | AB              | 641                                 | 2/17/2012            | H.1              | GII.4 (New Orleans 2009)           | KX608859      |
|         |           |                 |                                     | 7/19/2012            | H.3              | GII.4 (New Orleans 2009)           | KX608860      |
|         |           |                 |                                     | 7/24/2012            | H.4              | GII.4 (New Orleans 2009)           | KX608861      |
|         |           |                 |                                     | 9/5/2012             | H.5              | GII.4 (New Orleans 2009)           | KX608862      |
|         |           |                 |                                     | 9/18/2012            | H.6              | GII.4 (New Orleans 2009)           | KX608863      |
| I       | Leukemia/ALL | A               | 417                                 | 2/18/2012            | I.1              | GII.4 (New Orleans 2009)           | KX608864      |
| J       | PID/Hyper IgE | A               | 1                                   | 2/22/2012            | J.1              | GII.4 (New Orleans 2009)           | KX608865      |
| K       | Solid tumor | A               | 1                                   | 2/28/2012            | K.1              | GII.4 (New Orleans 2009)           | KX608866      |
| L       | Aplastic anemia | B               | 34                                  | 4/6/2012             | L.2              | GII.4 (Den Haag 2006b)             | KX608867      |
| M       | PID/IRAK4 deficiency | AB              | 385                                 | 4/2/2012             | M.1              | GII.4 (not assigned)               | KX608868      |
|         |           |                 |                                     | 7/14/2012            | M.4              | GII.4 (not assigned)               | KX608869      |
| O       | PID/PLAID  | O               | 304                                 | 5/6/2011             | O.1              | GII.4 (not assigned)               | KX608870      |
| N       | PID/SCID   | AB              | 16                                  | 3/10/2011            | N.2              | GII.3                              | KX608871      |
| P       | PID/SCID   | B               | 677                                 | 7/22/2011            | P.1              | GI.2                               | KX608872      |
| Q       | Lymphoproliferative disorder | B               | 1                                   | 11/21/2011           | Q.1              | GI.1                               | KX608873      |
| R       | Leukemia/CLL | O               | 1                                   | 2/3/2012             | R.1              | GI.3                               | KX608874      |

(Note: Patients B, C, and N were enrolled in a viral pathogens protocol before the start of the retrospective review summarized in Table 1.)

Abbreviations: ALL, acute lymphocytic leukemia; CLL, chronic lymphocytic leukemia; CVID, common variable immune deficiency; HIV, human immunodeficiency virus; Ig, immunoglobulin; IRAK4, interleukin-1 receptor-associated kinase-4; NIH, National Institutes of Health; PID, primary immunodeficiency; PLAID, plaid syndrome (phospholipase C-gamma 2-associated antibody deficiency and immune dysregulation; SCID, severe combined immune deficiency.

* Duration of norovirus shedding based on data from clinician-ordered tests sent to NIH microbiology laboratory during study period. The precise start and end dates for each infection were not known.
identified. Another of the closest genetic relationships (27 nucleotide differences) was between the ORF2 of noroviruses in the Den Haag 2006b cluster that were associated with infection in Patients C and L. Again, no common link in exposure could be identified based on medical records review.

Chronic norovirus infections were present in several patients. Patient A (who had PID and received immune globulin therapy) had the most prolonged shedding of norovirus (939 days or 2.6 years) (Table 2). We modeled the evolution of the GII.4 capsid sequence (an Apeldoorn 2007 variant) over time. As noted for other immunocompromised individuals, the majority of amino acid substitutions occurred in the surface exposed protruding (P) domain of the capsid [38, 39]. The mechanisms responsible for evolution in the major antigenic and receptor binding sites of the viral capsid will require further investigation.

**DISCUSSION**

We describe the prevalence of norovirus infection among immunocompromised individuals referred to the NIH Clinical Center. In our cohort, norovirus and *C. difficile* were the most commonly detected enteric pathogens, with prevalence rates...
of 13% and 16%, respectively. Our findings are consistent with studies conducted in similar populations: among solid organ and hematopoietic stem cell transplant recipients, norovirus was identified in 25 (22%) of 116 pediatric patients and was the most common enteric pathogen identified [18]. In a cohort of 62 children with primary immune deficiencies, norovirus was the most common pathogen identified, found in up to 17.7% of patients systematically screened [19]. Likewise, Echenique et al [23] reported that norovirus and C. difficile were the predominant enteric pathogens found in solid organ transplant recipients. As the ability to detect enteric pathogens improves with the availability of sensitive multiplex diagnostic assays, data concerning the risk factors, prevalence, and relative disease burden of norovirus in immunocompromised hosts will further define high-risk populations.

Noroviruses are known to establish persistent infections in immunocompromised individuals, and chronically infected patients could be a reservoir for the emergence of new norovirus strains over prolonged periods [40]. Moreover, nosocomial transmission and outbreaks have been linked to immunodeficient patients [41–43]. Although several patients in our study showed evidence of chronic infection with the same virus genotype over sustained periods, we did not find evidence of transmission of these specific strains within the NIH Clinical Center. The reason for this may be 2-fold: first, noroviruses may acquire mutations over time that affect their transmission and virulence; and second, rigorous infection control measures, including contact isolation, have been shown to prevent spread in the hospital [44]. An epidemiologic investigation in a pediatric tertiary care hospital attributed the absence of endemic enteric viruses in their setting to rigorous infection control [45]. Although some norovirus transmission may have occurred among the non-immunodeficient patients not tested for norovirus, we think this is unlikely given that all non-immunodeficient patients tested but excluded from our analysis were negative for norovirus, and no norovirus outbreaks were detected during the study period. Future studies with systematic screening for norovirus would provide a broader view of norovirus shedding and transmission across all patient populations in this setting. The risk that persistent norovirus shedding poses for spread to susceptible hosts is an important area of future investigation that will be facilitated by cell culture systems and animal models that can assay norovirus infectivity in clinical samples.

Our phylogenetic analysis of the GII.4 noroviruses showed genetic clustering of a specific norovirus strain within each patient, but not among patients, indicating that an endemic GII.4 norovirus strain was not present in the hospital. The seasonal pattern of virus detection, with a peak in the winter months (November–March), is consistent with the known seasonality of norovirus, the “winter vomiting disease” [2]. These data suggest that patients are likely exposed to norovirus in the community during the outbreak season when the risk of infection is highest in the general population. Once exposed, immunocompromised individuals vary in their ability to clear virus infection, and the virus may become chronic. Our data showed that patients maintained the same virus strain (albeit evolving) when chronically infected, which is consistent with several studies that have shown persistence of the same virus strain in an individual over time [38, 46]. Considering that formerly dominant GII.4 variants were detected in our cohort, it is possible that a number of these patients were infected years ago. Clearance and reinfection with a new norovirus has been reported in immunocompromised patients [18], so continued monitoring of our patient cohort with molecular tools will be needed to better define the extent of this risk.

The primary limitation of our study is that patients included in this retrospective cohort analysis represent a selected group of patients screened for norovirus and other gastrointestinal pathogens based on physician discretion, rather than through a systematic prospective approach. Nonetheless, the similarity of the norovirus prevalence found in our cohort to that for other immunocompromised groups studied, in both representative and nonsystematic samples, indicates that these estimates are likely to represent the true burden of norovirus in this population. Patients screened for norovirus are more likely to be those with clinically significant acute or persistent diarrhea, so the prevalence shown here is likely to represent clinically significant diarrhea. However, the causal relationship of norovirus with diarrhea in immunocompromised individuals needs further study because gut homeostasis is profoundly affected in many of these conditions and diarrhea is common. In addition, future studies with systematic follow-up among defined cohorts of immunocompromised persons will be useful in identifying factors related to persistence and clearance of norovirus infections.

**CONCLUSIONS**

Based on the findings in this and other similar studies that norovirus and C. difficile are the most common etiologic agents of diarrhea in immunocompromised individuals, we concur with Echenique et al [23] that screening for etiologic agents of diarrhea should at a minimum include targeting these 2 major pathogens. Increased use of multiplex panels in symptomatic patients should improve diagnosis and treatment of persistent diarrhea in patients with underlying immune deficiencies. The risk for exposure and chronic infection in patients with underlying immune deficiencies will be reduced.
Acknowledgments

We thank Dr. Jeffrey I. Cohen and Siu-Ping Turk for their guidance and support, and we thank the clinical care team. We also thank the patients who participated in this research.

Financial support. This work was supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), and the NIH Clinical Center.

Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

References

1. Payne DC, Vinje J, Snlæggi PG, et al. Norovirus and medically attended gastroenteritis in U.S. children. N Engl J Med 2013; 368:1121–30.
2. Ahmed SM, Lopman BA, Levy K. A systematic review and meta-analysis of the global seasonality of norovirus. PLoS One 2013; 8:e75922.
3. Koo HL, Neill FH, Estes MK, et al. Noroviruses: the most common pediatric viral enteric pathogen at a large university hospital after introduction of rotavirion vaccination. J Pediatric Infect Dis Soc 2013; 2:57–60.
4. Hall AJ, Curns AT, McDonald LC, et al. The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999–2000. Clin Infect Dis 2012; 55:216–23.
5. Atmar RL, Bernstein DI, Harro CD, et al. Norovirus vaccine against experimental human Norwalk virus illness. N Engl J Med 2011; 365:2178–87.
6. Bernstein DI, Atmar RL, Lyon GM, et al. Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults. J Infect Dis 2015; 211:870–8.
7. Riddle MS, Walker RI. Status of vaccine research and development for norovirus. Arch Virol 2013; 158:2059–68.
8. Alibabadi N, Lopman BA, Parashar UD, Hall AJ. Progress toward norovirus vaccines: considerations for further development and implementation in potential target populations. Expert Rev Vaccines 2015; 14:1241–53.
9. Chen Z, Sosnovtsev SV, Bok K, et al. Development of Norwalk virus-specific monoclonal antibodies with therapeutic potential for the treatment of Norwalk virus gastroenteritis. J Virol 2013; 87:9547–57.
10. Kou B, Crawford SE, Ajami NJ, et al. Characterization of cross-reactive norovirus-specific monoclonal antibodies. Clin Vaccine Immunol 2015; 22:160–7.
11. Green KY. Caliciviridae: the noroviruses. In: Knipe DM, Howley PM, eds. Fields Virology. 6th ed. Vol I, Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2013; pp 582–608.
12. Kroneman A, Vega E, Vennema H, et al. Proposal for a unified norovirus nomenclature and genotyping. Arch Virol 2013; 158:2059–68.
13. Vinje J. Advances in laboratory methods for detection and typing of norovirus. J Clin Microbiol 2015; 53:373–81.
14. Kroneman A, Verhoef L, Harris J, et al. Analysis of integrated virological and epidemiological reports of norovirus outbreaks collected within the Foodborne Viruses in Europe network from 1 July 2001 to 30 June 2006. J Clin Microbiol 2008; 46:2959–65.
15. Bull RA, Eden JS, Rawlinson WD, White PA. Rapid evolution of pandemic noroviruses of the GI.4 lineage. PLoS Pathog 2010; 6:e1000831.
16. Mai H, Gao Y, Cong X, et al. GI4 Sydney 2012 norovirus infection in immunocompromised patients in Beijing and its rapid evolution in vivo. J Med Virol 2016; 88:224–33.
17. Lindesmith LC, Beltramezzo M, Donaldson EF, et al. Immunogenetic mechanisms driving norovirus GI.4 antigenic variation. PLoS Pathog 2012; 8:e1002705.
18. Ye X, Van JN, Munoz FM, et al. Noroviruses as a cause of diarrhea in immunocompromised pediatric hematopoietic stem cell and solid organ transplant recipients. Am J Transplant 2015; 15:1874–81.
19. Frange F, Touzet F, Debpe M, et al. Prevalence and clinical impact of norovirus fecal shedding in children with inherited immune deficiencies. J Infect Dis 2012; 206:1269–74.
20. Green KY. Norovirus infection in immunocompromised hosts. Clin Microbiol Infect 2014; 20:717–23.
21. Osborne CM, Montano AC, Robinson CC, et al. Viral gastroenteritis in children in Colorado 2006–2009. J Med Virol 2015; 87:931–9.
22. Roodie C, Paul JP, Benjamim R, et al. Allogeneic hematopoietic stem cell transplantation and norovirus gastroenteritis: a previously unrecognized cause of morbidity. Clin Infect Dis 2009; 49:1061–8.
23. Echenique IA, Penagonda S, Slosor V, et al. Diagnostic yields in solid organ transplant recipients admitted with diarrhea. Clin Infect Dis 2015; 60:729–37.
24. Kageyama T, Kojsima S, Shinohara M, et al. Broadly reactive and highly sensitive assay for Norwalk-like viruses based on real-time quantitative reverse transcription-PCR. J Clin Microbiol 2003; 41:1548–57.
25. Cohen J, Fahe M, Kemp MA, et al. Human herpesvirus 6-A, 6-B, and 7 in vitro fluid samples. J Med Virol 2010; 82:996–9.
26. Jiang X, Huang PW, Zhong WM, et al. Design and evaluation of a primer pair that detects both Norwalk- and Sapporo-like caliciviruses by RT-PCR. J Virol Methods 1999; 83:145–54.
27. Kroneman A, Vennema H, Deforce K, et al. An automated genotyping tool for enteroviruses and noroviruses. J Clin Virol 2011; 51:121–5.
28. Kojima S, Kageyama T, Fukushima S, et al. Genogroup-specific PCR primers for detection of Norwalk-like viruses. J Virol Methods 2002; 100:107–14.
29. Green KY, Belliot G, Taylor JL, et al. A predominant role for Norwalk-like viruses as agents of epidemic gastroenteritis in Maryland nursing homes for the elderly. J Infect Dis 2002; 185:133–46.
30. Bok K, Abente EJ, Reaple-Quintero M, et al. Evolutionary dynamics of GII.4 noroviruses over a 34-year period. J Virol 2009; 83:11890–901.
31. Tamura K, Stecher G, Peterson D, et al. MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol 2013; 30:2725–9.
32. Petersen EF, Goddard TD, Huang CC, et al. UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem 2004; 25:1605–12.
33. Huo AP, McReynolds LJ, Holland SM. GATA2 deficiency. Curr Opin Allergy Clin Immunol 2015; 15:104–9.
34. Ravou-Clouet N, Belliot G, Le Pendu J. Noroviruses and histo-blood groups: the impact of common host genetic polymorphisms on virus transmission and evolution. Rev Med Virol 2013; 23:355–66.
35. Lindesmith LC, Donaldson EF, Luboe AB, et al. Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med 2008; 5:e31.
36. Eden JS, Tanaka MM, Bonsi MF, et al. Recombination within the pandemic norovirus GII.4 lineage. J Virol 2013; 87:6270–82.
37. Gould LH, Walsh KA, Vieira AR, et al. Surveillance for foodborne disease outbreaks - United States, 1998–2008. MMWR Surveill Summ 2013; 62:1–34.
38. Bull RA, Eden JS, Luciani F, et al. Contribution of intra- and interhost dynamics to norovirus evolution. J Virol 2012; 86:3219–29.
39. Vega E, Donaldson E, Huynh J, et al. RNA populations in immunocompromised patients as reservoirs for novel norovirus variants. J Virol 2014; 88:14184–96.
40. Karst SM, Baric RS. What is the reservoir of emergent human norovirus strains? J Virol 2015; 89:5756–9.
41. Holzknecht BJ, Franck KT, Nielsen RT, et al. Sequence analysis of the capsid gene during a genotype II.4 dominated norovirus season in one university hospital: identification of possible transmission routes. PLoS One 2015; 10:e0115331.
42. Sukhrie FH, Siebigaj JJ, Beersma MF, Koopmans M. Chronic shedding as reservoir for nosocomial transmission of norovirus. J Clin Microbiol 2010; 48:4303–5.
43. Kundu S, Lockwood J, Deplede DP, et al. Next-generation whole genome sequencing identifies the direction of norovirus transmission in linked patients. Clin Infect Dis 2013; 57:407–14.
44. MacCannell T, Umscheid CA, Agarwal RK, et al. Guideline for the prevention and control of norovirus gastroenteritis outbreaks in healthcare settings. Infect Control Hosp Epidemiol 2011; 32:939–69.
45. Gallimore CL, Cubbit DW, Richards AF, Gray JJ. Diversity of enteric viruses detected in patients with gastroenteritis in a tertiary referral paediatric hospital. J Med Virol 2004; 73:443–9.
46. Nilsson M, Hedlund KO, Thorhagen M, et al. Evolution of human calicivirus RNA in vivo: accumulation of mutations in the protruding P2 domain of the capsid leads to structural changes and possibly a new phenotype. J Virol 2003; 77:1317–24.
47. Kaufman SS, Green KY, Korba BE. Treatment of norovirus infections: moving antivirals from the bench to the bedside. Antiviral Res 2014; 105:80–91.